tiprankstipranks
Matinas BioPharma (MTNB)
NYSE MKT:MTNB

Matinas BioPharma (MTNB) Financial Statements

1,443 Followers

Matinas BioPharma Financial Overview

Matinas BioPharma's market cap is currently ―. The company's EPS TTM is $-0.107; its P/E ratio is -1.67; Matinas BioPharma is scheduled to report earnings on August 7, 2024, and the estimated EPS forecast is $-0.03. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Sep 23Jun 23Mar 23Dec 22
Income Statement-
Total Revenue---$ 1.10M$ 1.06M
Gross Profit---$ 1.10M$ 1.06M
EBIT$ -5.31M$ -6.05M$ -6.06M$ 7.85M$ -3.63M
EBITDA$ -5.06M$ -5.80M$ -5.80M$ 8.12M$ -3.82M
Net Income Common Stockholders$ -5.31M$ -6.05M$ -6.06M$ 7.85M$ -3.63M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 13.76M$ 18.22M$ 22.56M$ 24.91M$ 28.81M
Total Assets$ 25.10M$ 29.79M$ 34.02M$ 38.26M$ 44.82M
Total Debt$ 3.56M$ 3.71M$ 3.85M$ 3.99M$ 4.12M
Net Debt$ -10.20M$ -14.51M$ -18.71M$ -20.92M$ -24.69M
Total Liabilities$ 5.86M$ 6.64M$ 6.17M$ 5.64M$ 8.18M
Stockholders Equity$ 19.25M$ 23.15M$ 27.85M$ 32.63M$ 36.64M
Cash Flow-
Free Cash Flow$ -4.58M$ -4.43M$ -2.40M$ -4.09M$ -4.34M
Operating Cash Flow$ -4.58M$ -4.42M$ -2.19M$ -4.09M$ -4.30M
Investing Cash Flow$ 2.96M$ 1.08M$ 6.20M$ 3.00M$ -42.01K
Financing Cash Flow$ -1.00K$ -1.00K$ -1.00K$ -4.00K$ -4.64K
Currency in USD

Matinas BioPharma Earnings and Revenue History

Matinas BioPharma Debt to Assets

Matinas BioPharma Cash Flow

Matinas BioPharma Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis